In closing, targeting LAT1 provides another method to reduce intracellular polyamines beyond the known biosynthetic inhibitors like difluoromethylornithine (DFMO) and polyamine depletion strategies, which in general have provided beneficial outcomes in several cancer models [36,37,38,39,40]. The gene discussed is SLC7A5; the disease is cancer.